Literature DB >> 19076788

Developments in the management of mycetomas.

M Ameen1, R Arenas.   

Abstract

Mycetomas are chronic, granulomatous, subcutaneous infections caused by either eumycetes fungi or actinomycetes bacteria, giving rise to eumycetomas and actinomycetomas, respectively. The disease is endemic in many tropical countries, and is characterized by slow progression with risks of bone and visceral involvement. Treatment consists of long courses of antifungals and antibacterials, often combined with surgery. Drug resistance, poor response to treatment, and high rates of relapse have prompted trials of novel antibiotics and antifungals. This article discusses the potential of new treatment regimens and recent developments and improvements in diagnostics and prognostics, which will improve disease management.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19076788     DOI: 10.1111/j.1365-2230.2008.03028.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  12 in total

1.  In vitro activity of ACH-702, a new isothiazoloquinolone, against Nocardia brasiliensis compared with econazole and the carbapenems imipenem and meropenem alone or in combination with clavulanic acid.

Authors:  Lucio Vera-Cabrera; Mayra Paola Campos-Rivera; Wendy G Escalante-Fuentes; Michael J Pucci; Jorge Ocampo-Candiani; Oliverio Welsh
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

Review 2.  Madura foot: two case reports, review of the literature, and new developments with clinical correlation.

Authors:  Eric A White; Dakshesh B Patel; Deborah M Forrester; Christopher J Gottsegen; Emily O'Rourke; Paul Holtom; Timothy Charlton; George R Matcuk
Journal:  Skeletal Radiol       Date:  2013-10-23       Impact factor: 2.199

3.  Case report: Non-invasive management of Madura foot with oral posaconazole and ciprofloxacin.

Authors:  Amit M Sharma; Namita Sharma; Amritpal Nat; Meghan Rane; Timothy P Endy
Journal:  Am J Trop Med Hyg       Date:  2014-10-27       Impact factor: 2.345

4.  Eumycetoma of the hand caused by Leptosphaeria tompkinsii and refractory to medical therapy with voriconazole.

Authors:  Katharine E Cartwright; Tristan W Clark; Abid M Hussain; Martin Wiselka; Andrew Borman; Elizabeth M Johnson
Journal:  Mycopathologia       Date:  2011-05-13       Impact factor: 2.574

Review 5.  Melanized fungi in human disease.

Authors:  Sanjay G Revankar; Deanna A Sutton
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

Review 6.  Actinomycetoma in SE Asia: the first case from Laos and a review of the literature.

Authors:  Sayaphet Rattanavong; Sivay Vongthongchit; Khamhou Bounphamala; Phouvong Vongphakdy; Jacques Gubler; Mayfong Mayxay; Rattanaphone Phetsouvanh; Ivo Elliott; Julie Logan; Robert Hill; Paul N Newton; David Dance
Journal:  BMC Infect Dis       Date:  2012-12-12       Impact factor: 3.090

7.  Concepts and principles of photodynamic therapy as an alternative antifungal discovery platform.

Authors:  Tianhong Dai; Beth B Fuchs; Jeffrey J Coleman; Renato A Prates; Christos Astrakas; Tyler G St Denis; Martha S Ribeiro; Eleftherios Mylonakis; Michael R Hamblin; George P Tegos
Journal:  Front Microbiol       Date:  2012-04-10       Impact factor: 5.640

8.  Does the benefit of salvage amputation always outweigh disability in drug-failure mycetoma?: a tale of two cases.

Authors:  Prasanta K Maiti; Bipasa Chakraborty; Sudipta Ghosh; Abhishek De
Journal:  Indian J Dermatol       Date:  2015 Jan-Feb       Impact factor: 1.494

Review 9.  Mycetoma: a clinical dilemma in resource limited settings.

Authors:  Pembi Emmanuel; Shyam Prakash Dumre; Stephen John; Juntra Karbwang; Kenji Hirayama
Journal:  Ann Clin Microbiol Antimicrob       Date:  2018-08-10       Impact factor: 3.944

10.  Fusarium subglutinans: A new eumycetoma agent.

Authors:  Pablo Campos-Macías; Roberto Arenas-Guzmán; Francisca Hernández-Hernández
Journal:  Med Mycol Case Rep       Date:  2013-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.